BioAdvance - Articles
Newsroom >> BioAdvance and Regional News

Today’s Top Regional Life Sciences Stories from Business Wire

Mitsubishi Chemical Medience Corporation Switches to Provantis
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem, a leading provider of early drug development software solutions, announced today that Mitsubishi Chemical Medience Corporation (MCM) has purchased the Provantis preclinical software solution. Following an extensive competitive evaluation MCM decided to replace its existing data collection systems with the fully integrated Provantis solution to manage Preclinical study processes at their research facilities in Kashima and Kumamoto, Japan. MCM is one of
Kay Bross Named Program Director, Member & Vendor Relations, SAFE-BioPharma Association
FT. LEE, N.J.--(BUSINESS WIRE)--Kay Bross has been named Program Director, Member and Vendor Relations for SAFE-BioPharma Association, the non-profit association that created and manages the SAFE-BioPharma® digital identity and digital signature standard for the pharmaceutical and healthcare industries. Ms. Bross, who served as a member of the association’s Board of Directors, is responsible for building and managing relationships with the association’s growing member and vendor
Rosetta Genomics to Present at the 22nd Annual Roth OC Growth Stock Conference
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced that Kenneth A. Berlin, president and chief executive officer, will be presenting a corporate update at the 22nd Annual Roth OC Growth Stock Conference on Tuesday, March 16, 2010 at 3:30 p.m. (Pacific Time) at the Ritz Carlton Laguna Niguel in Dana Point, California. A live webcast of the presentation will be available by going to the inve
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
ClearCount Medical Solutions Appoints David Haffner as CFO
PITTSBURGH--(BUSINESS WIRE)--ClearCount Medical Solutions, an innovator of patient safety solutions for the operating room, today announced that it has appointed David Haffner as its Chief Financial Officer. In this role, Mr. Haffner will oversee the day-to-day financial operations of the company, and will be responsible for the financial strategy as the company’s product sales increase. “It’s an honor to be part of a team at a rapidly growing medical device company dedicated t
Advaxis Confirms Long-Term Stability of Listeria-Based Immunotherapeutics’ Formulations
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Confirms Long-Term Stability of Listeria-Based Immunotherapeutics’ Formulations GMP Practices Potentially Viable for Commercialization Protocol
CardiacAssist will host TandemHeart® 2000th Case Symposium and exhibit at American College of Cardiology annual meeting
PITTSBURGH--(BUSINESS WIRE)--CardiacAssist Inc. announced today that it will exhibit its TandemHeart® System (Booth 356) in Atlanta at the American College of Cardiology (ACC) 59th Annual Scientific Session that begins on Sunday, March 14th, at the Georgia World Congress Center. Additionally, CardiacAssist will host “Clinical Innovations in TandemHeart Support Symposium and User Group Meeting”—by invitation only—on Sunday, March 14th, with case presentations by Dr. N
Enzon’s Debt is Reduced by $116 Million
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered. The sale of the specialty phar
Genta Announces $25 Million Financing
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA) announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions. Proceeds of the financing will be used to ensure adequate followup to determine overall survival results from Gent
PolyMedix to Present at The Roth 22nd Annual Growth Stock Conference
RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), will be presenting at the Roth 22nd Annual Growth Stock Conference taking place March 15 – 17, 2010 at the Ritz-Carlton Laguna Niguel, CA.